Traws PharmaTRAW
13F holders, Q2 2025 (June 30)19holders +1
4new positions
3sold out
$1.48avg. 13F price*
At the end of Q2 2025, 19 institutions reported holding Traws Pharma Inc. (TRAW) in their 13F filings, up 1 from Q1 2025. 4 opened new positions and 3 sold out. The largest holders were Orbimed Advisors LLC ($896K), Adage Capital Partners Gp, L.L.C. ($488K) and Vestal Point Capital, LP ($222K).
- Company
- Traws Pharma Inc.
- CUSIP
- 68232V884
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $49K |
| Exits | 3 | $1.1M |
All 13F filers, Q1 2025 → Q2 2025: 35,758 shares bought and 504,580 shares sold, net −468,822 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 19 holders
| Orbimed Advisors LLC | 0.02% | No change | 605,531 | $896K |
| Adage Capital Partners Gp, L.L.C. | 0.00% | No change | 330,000 | $488K |
| Vestal Point Capital, LP | 0.01% | Reduce -14.4% | 149,800 | $222K |
| Alyeska Investment Group, L.P. | 0.00% | No change | 52,630 | $78K |
| Geode Capital Management, LLC | 0.00% | Add +7.0% | 35,725 | $53K |
| Ikarian Capital, LLC | 0.01% | No change | 28,493 | $42K |
| Two Sigma Securities, LLC | 0.00% | New | 17,169 | $25K |
| Two Sigma Investments, LP | 0.00% | New | 16,063 | $24K |
| Vanguard Group Inc. | 0.00% | No change | 13,173 | $19K |
| BlackRock, Inc. | 0.00% | No change | 9,956 | $15K |
| UBS Group AG | 0.00% | Reduce -79.0% | 3,006 | $4K |
| Morgan Stanley | 0.00% | Reduce -0.8% | 719 | $1K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -78.3% | 706 | $1K |
| SBI Securities Co., Ltd. | 0.00% | Reduce -68.0% | 162 | $240 |
| Raymond James Financial Inc. | 0.00% | New | 102 | $151 |
| Vermillion & White Wealth Management Group, LLC | 0.00% | No change | 96 | $142 |
| Bank of America Corp. | 0.00% | Add +23.7% | 94 | $139 |
| Citigroup Inc. | 0.00% | New | 60 | $89 |
| FMR LLC | 0.00% | No change | 2 | $3 |
"% of holder's portfolio" is TRAW's weight in each manager's 13F, not the share of Traws Pharma Inc. the manager owns.